BEIJING: China has equalized or surpassed the developed nations’ pharma standards over a period of time.
With 30 years of experience in cooperation with China, our progress is accompanied by the dividend of the development of China’s pharmaceutical industry,”highlighted Waheed Ahmed, Chief Executive of Shaigan Pharmaceuticals Pvt Ltd at the CPHI & PMEC China.
As Asia’s leading pharmaceutical show for trading, knowledge sharing and networking, CPHI & PMEC China spans all industry sectors along the pharmaceutical supply chain including APIs, excipients, finished dosage, natural exacts, biophama & CDMOs, animal health&feed, medical supplies, etc.
Waheed, who has been attending the expo since 1995, noted that CPHI China is becoming more and more informative due to the major R&D work being carried out in China. China, Pakistan’s largest trading partner and the largest producer of API, attaches importance to investing in chemical labs and training scientists. China’s key technologies are developing rapidly, and the quality of pharmaceutical and mechanical products is reliable, he explained. “This time I am exploring future technologies and newly developed products, especially in biosimilers and new drug delivery systems,” Waheed mentioned, “meeting my over 15 collaborative partners who are all old friends at the expo and witnessing their growth is always a pleasure and opportunity to tap new business range.” At the expo, Jack, head of a pharmaceutical packaging machinery manufacturing enterprise integrating R&D, production and sales service told Gwadar Pro that Pakistan has a huge pharmaceutical market of 250 million people, making it one of the most promising pharmaceutical consumer markets.
The industry has grown rapidly in recent years and its production capacity has greatly increased, as can be told from the fact that the equipment they provide has been upgraded from small and low-speed machinery to large and high-speed machinery. –Agencies
